in Hb A1c assays and to be useless for clinical diagnostic purposes (1–4), these 2 examples show that considering labile Hb A1c values when validating Hb A1c results has potential utility for monitoring conformity with preanalytical procedures and for ensuring the global quality of laboratory performance. We propose, however, that the estimated labile Hb A1c value be used only as a tool in interpreting Hb A1c results. We recommend that labile Hb A1c values should not be used separately, because the analyzers that separate labile Hb A1c from carbamylated Hb and Hb A1c are not calibrated for quantifying these subcomponents. Moreover, any problem that could alter the interpretation of labile Hb A1c must be taken into account. For example, extended storage of samples before analysis could cause red cells to consume glucose, which could lead to the dissociation of labile Hb A1c.

We believe that each Hb chromatogram must be studied carefully. Useful information may be obtained from all Hb fractions (5). Optimal use of Hb A1c values in clinical practice may be achieved only when both physicians (i.e., those ordering the test) and medical biologists (those performing the assays and interpreting the results) fully exert their respective responsibilities.

References

Emmanuelle Corb´e-Guillard
St´ephane Jaissen
C´ecile Pileire
Philippe Gillery*

Laboratory of Paediatric Biology and Research
American Memorial Hospital
University Hospital of Reims and Laboratory of Biochemistry and Molecular Biology
UMR CNRS/URCA no. 6237
Faculty of Medicine
Reims, France

* Address correspondence to this author at: Laboratoire de Biologie et de Recherche Pediatriques
American Memorial Hospital
CHU de Reims
47 rue Cognacq-Jay
F-51092 Reims Cedex, France
Fax +33-3-26-78-38-82
E-mail pgillery@chu-reims.fr

Previously published online at DOI: 10.1373/clinchem.2010.152819

Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria—a Substudy of the ACCORD Trial

To the Editor:

The presence of microalbuminuria in patients with diabetes mellitus (DM)1 is associated with a 3- to 5-fold higher risk of cardiovascular mortality than in patients with DM without microalbuminuria and a risk of progression to end-stage kidney disease that is 10-fold higher. Predicting and/or preventing the development of albuminuria have substantial potential to improve outcomes and reduce costs in patients with DM.

Catalytic iron, also known as labile iron, consists of chemical forms that can participate in redox cycling. This property makes catalytic iron potentially hazardous because it can participate in the generation of powerful oxidant species, such as hydroxyl radicals and/or reactive iron–oxygen complexes such as the ferryl or perferryl ion (1, 2). Animal models of glomerular disease exhibit increased urinary catalytic iron, and administration of an iron chelator reduces concentrations and protects against proteinuria (3). These findings suggest a pathogenetic role for catalytic iron. We postulated that the concentrations of catalytic iron may be higher in patients with DM, and if that is so, higher concentrations could precede the occurrence of proteinuria.

We conducted an ancillary study in a subgroup of 9 clinical centers (in 2 networks from the southeastern and western regions of the US) of the NIH-sponsored ACCORD (Action to Control Car-

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors’ Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of interest.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.
diovascular Risk in Diabetes) Trial (4) to determine the prevalence of increased catalytic iron in participants with nonpathologic renal function and the absence of microalbuminuria (<30 μg/mg creatinine) at baseline. We had 507 urine samples available and suitable for the analysis of catalytic iron, as well as complete clinical data. Of these samples, we randomly selected 167 samples for additional measurement of urinary isoprostane, a marker of oxidative stress.

We used the bleomycin-detectable iron assay to measure catalytic iron in urine (5). F$_{2}$t-isoprostane–isoprostane concentrations were measured at the University of Colorado with the liquid chromatography–tandem mass spectrometry assay (6). We transformed data for the following outcome variables: the concentration ratios of urinary bleomycin-detectable iron to creatinine and of urinary microalbumin to creatinine. Logistic regression models fitted to determine predictors of abnormal urinary iron and isoprostane concentrations included age, sex, race, weight, body mass index, LDL, and HDL as covariates. SAS software (version 9.1; SAS Institute) was used to analyze the data.

We used the NCCLS (now CLSI) guidelines (7) to establish a reference interval for the ratio of urinary bleomycin-detectable iron to creatinine [95% CI, 140.9–253.2 nmol/mg (15.9–28.6 nmol/μmol); mean, 197.0 nmol/mg (22.3 nmol/μmol)] with a population of 100 healthy people from New Orleans (50 men and 50 women; mean age, 37.4 years; mean body mass index, 22.9 kg/m$^2$) (5). None of the participants had DM, hepatitis C, or hemochromatosis. This group of healthy individuals served as an external reference population (control group) for the ACCORD study participants.

In our study, 21% (35 of 167) of the participants had increased urinary isoprostane (>120 pmol/mmol creatinine). There was no relationship between the ratio of urinary bleomycin-detectable iron to creatinine and the urinary isoprostane concentration, either in the entire cohort ($r = -0.12; P = 0.12$) or in the patients with higher urinary isoprostane concentrations.

In this cross-sectional study, we observed increased urinary catalytic iron concentrations in 54% of the participants with DM without mi-

---

**Table 1. Clinical characteristics of patients with and without increased urinary catalytic iron.**

<table>
<thead>
<tr>
<th></th>
<th>Without increased iron (n = 231)</th>
<th>With increased iron (n = 276)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary catalytic iron, nmol/mg</td>
<td>83.3 (90.5)</td>
<td>623.6 (405.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Urinary isoprostane, pmol/mmol</td>
<td>111.1 (156.4)</td>
<td>101.4 (235.0)</td>
<td>0.76</td>
</tr>
<tr>
<td>Age, years</td>
<td>64.5 (5.6)</td>
<td>64.5 (5.8)</td>
<td>0.94</td>
</tr>
<tr>
<td>Males/female sex, n</td>
<td>123/108</td>
<td>140/136</td>
<td>0.57</td>
</tr>
<tr>
<td>Approximate DM duration, years</td>
<td>13.1 (7.5)</td>
<td>12.8 (7.4)</td>
<td>0.63</td>
</tr>
<tr>
<td>UALB/Ucr, μg/mg</td>
<td>26.2 (128.3)</td>
<td>18.3 (32.9)</td>
<td>0.37</td>
</tr>
<tr>
<td>Plasma creatinine, mg/dL</td>
<td>0.8 (0.2)</td>
<td>0.8 (0.2)</td>
<td>0.46</td>
</tr>
<tr>
<td>Hemoglobin A$_{1c}$, %</td>
<td>8.2 (1.1)</td>
<td>8.2 (1.1)</td>
<td>0.47</td>
</tr>
<tr>
<td>Systolic BP, mmHg</td>
<td>136.6 (14.8)</td>
<td>135.6 (16.7)</td>
<td>0.5</td>
</tr>
<tr>
<td>Diastolic BP, mmHg</td>
<td>76.9 (9.5)</td>
<td>76.3 (10.1)</td>
<td>0.49</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>191.8 (44.4)</td>
<td>197.1 (42.8)</td>
<td>0.18</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>110.7 (35.0)</td>
<td>114.7 (37.2)</td>
<td>0.22</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>42.8 (11.1)</td>
<td>43.5 (12.2)</td>
<td>0.49</td>
</tr>
<tr>
<td>BDI/Ucr, nmol/mg</td>
<td>95.6 (72.1)</td>
<td>846.3 (593.4)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

* Data are presented as the mean (SD) except for the sex data.

b UALB/Ucr, urine microalbumin–urine creatinine ratio; BP, blood pressure; BDI/Ucr, urine bleomycin-detectable iron–urine creatinine ratio.
croalbuminuria and with a non-pathologic renal function. Our study has limitations. The ACCORD trial enrolled participants with DM and an additional cardiovascular risk factor. Participants were in different stages of DM. None of the traditional risk factors (highly prevalent in this population) were associated with increased urinary catalytic iron in participants without microalbuminuria. Thus, if urinary catalytic iron is associated with future cardiovascular or renal events, that association is likely to be independent of the covariates we examined. Urinary catalytic iron has potential to be useful as an independent predictor of risk of nephropathy and cardiovascular events.

This cross-sectional study represents an initial step in the development of a biomarker of risk prediction—the demonstration that urinary catalytic iron is abnormal in a population with DM and cardiovascular risk factors but without increased urinary albumin. Because catalytic iron potentially provides a direct target for a therapeutic intervention, we recommend that longitudinal studies be conducted to examine the potential role of urinary catalytic iron in identifying patients at risk for incident renal and cardiovascular events.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: J. Buse, Novo Nordisk, Amylin Pharmaceuticals, Becton Dickinson, Eli Lilly, Roche, GlycoMark, Wyeth, Daichi Sankyo, Bristol-Myers Squibb, LipoScience, MannKind, Veritas, Microset, GlaxoSmithKline, Abbott Laboratories, Exsulin, and GI Dynamics.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: J. Probstfield, Sanofi-Aventis; J. Buse, Novo Nordisk, Amylin Pharmaceuticals, Medtronic, Eli Lilly, Novartis, Tolerex, Osiris Therapeutics, Halozyme Therapeutics, Pfizer, Roche, Intekrin Therapeutics, Merck, Sanofi-Aventis, Dexcel, Johnson & Johnson, Bristol-Myers Squibb, and Fujisawa Pharmaceutical; V. Fonseca, NIH (ACCORD, TINSAL-2D), American Diabetes Association, and Tulane-Tulane Chair in Diabetes. T. Thethi, Eunice Kennedy Shriver National Institute of Child Health and Human Development (award number K12HD043451). Group: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is sponsored by the National Heart Lung and Blood Institute. We acknowledge the participation and support of the 9 clinical centers. The ACCORD steering and publication committees approved the manuscript. This study is also supported by the Clinical and Translational Research Center, which is supported in part or full by the Tulane/LSU Health Sciences Centers Clinical and Translational Research Education and Commercialization Project funded by the Louisiana Board of Regents.

Expert Testimony: J. Buse, Novo Nordisk.

Other Remuneration: Diabetes research at Tulane University Health Sciences Center is supported in part by the Susan Harling Robinson Fellowship in Diabetes Research and the Tulane-Tulane Alumni Chair in Diabetes.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health.

References


Tina Thethi2
Mohan Rajapurkar3
Patrick Walker4
Robertta McDuffie2
David C. Goff, Jr.5
Jeffrey Probstfield6
C. Lillian Yau7
Sudhir Shah8
Uwe Christians9
John Buse10
Vivian Fonseca2*

2 Tulane University Health Sciences Center
New Orleans, LA
3 Mulijibhai Patel Society for Research in Nephro-Urology
Nadiad, India
4 Nephropathology Associates
Little Rock, AR
5 Wake Forest University School of Medicine
Winston-Salem, NC
6 University of Washington School of Public Health
Seattle, WA
7 School of Public Health and Tropical Medicine
Tulane University
New Orleans, LA
8 University of Arkansas for Medical Sciences College of Medicine
Little Rock, AR
9 Department of Anesthesiology
University of Colorado at Denver and Health Sciences Center
Denver, CO
10 University of North Carolina Health Sciences
Chapel Hill, NC
Red Cell Transfusion Decreases Hemoglobin A₁c in Patients with Diabetes

To the Editor:

Hemoglobin A₁c (Hb A₁c) is a mainstay of diabetes diagnosis and management that allows clinicians to estimate the recent mean blood glucose concentration of a patient. Glycation of hemoglobin is an irreversible, nonenzymatic process that depends on the glucose concentration in red blood cells (RBCs), and Hb A₁c represents the integrated glucose concentration in RBCs over their life span.

RBC transfusion can complicate the interpretation of Hb A₁c values in diabetic patients because it introduces hemoglobin molecules exposed to glucose concentrations that may have been different from the glucose concentrations in the diabetic transfusion recipient. The potential effect of transfusion on Hb A₁c has been recognized for some time, but opinions on the direction of the effect are contradictory. Data from the older literature (1–3) suggest that the high concentration of glucose in RBC storage medium promotes glycation and causes Hb A₁c values to increase over time, which would predict that Hb A₁c might increase in transfused patients. This concept has been stated in a recent review article (4) and on consumer Web sites, such as Lab Tests Online (http://labtestsonline.org/understanding/analytes/a1c/test.html); however, a recent case in which a pathology resident was contacted to explain a patient’s Hb A₁c value decreasing from 7.4% to 5.4% in 3 days after the patient received 3 units of RBCs suggested that transfusion may lower Hb A₁c values in diabetic patients. Indeed, the majority of blood donors are not diabetic, and donor RBCs would dilute the increased Hb A₁c value (>6.5%) in a diabetic patient. To our knowledge, no study has used contemporary Hb A₁c methods to examine the effect of RBC storage conditions on Hb A₁c or the overall effect of RBC transfusion on Hb A₁c in patients.

To investigate these questions, we used an immunoassay (Siemens Dimension RxL) to measure Hb A₁c in 2 unused RBC units stored in additive storage medium (AS-1) under standard blood bank conditions. These 2 units were unacceptable for transfusion because they had been out of the control of the blood bank for >30 min. The Hb A₁c values for samples obtained from the units on their expiration date (42 days after collection) were 5.4% (B Rh-positive) and 5.7% (O Rh-positive), which are within our reference interval (<6.0%). The glucose concentrations in the blood units at this time were 36.9 mmol/L (665 mg/dL) and 32.5 mmol/L (586 mg/dL), confirming the supraphysiological glucose content of the RBC storage medium. We observed minimal increases in Hb A₁c values in the units after additional incubation at room temperature for 9 days (5.7% and 5.9%) and at 37 °C for another 14 days (6.0% and 6.0%). This finding strongly suggests that glycation of hemoglobin in stored RBC units is negligible despite the high glucose concentrations in stored RBC units.

To determine if RBC transfusion has a measurable effect on Hb A₁c in patients, we retrospectively queried an institutional review board–approved database of identified patient data from our hospital for patients who received RBC transfusions and had Hb A₁c measurements performed within 28 days before and 14 days after they received at least 1 RBC transfusion. We allowed a maximum of 7 days between the first and last transfusions for patients who received multiple transfusions; therefore, the maximum time between the pre- and posttransfusion Hb A₁c measurements was 49 days. Fig. 1 shows the change in Hb A₁c after transfusion for 45 patients who met the inclusion criteria. The Hb A₁c decreased in 31 (69%) of the patients overall and in all 21 patients whose pretransfusion Hb A₁c measurement was ≥7%. Of the 14 patients whose Hb A₁c value increased or remained unchanged, 12 had a pretransfusion Hb A₁c value of <6.5%; thus, one would not expect the transfusion of RBCs with a typical Hb A₁c value to have a large effect. The mean decrease in Hb A₁c across all patients was 0.829%, which is statistically significant (P = 0.00124, 2-sided paired t-test). The mean decrease for the 21 patients with pretransfusion values ≥7% was 1.97% Hb A₁c.

These results suggest that RBC transfusion will reduce the Hb A₁c concentration in diabetic patients. We did not design this study to fully characterize this phenomenon, but it does show that appreciable glycation does not occur during typical blood bank storage. Thus, we would expect decreased Hb A₁c values after transfusion to be most pronounced in patients who receive large transfusion volumes and/or who have a high pretransfusion Hb A₁c, because of dilution with RBCs containing typical amounts of Hb A₁c. Indeed, pa-